Although much more rare than its diabetic counterpart, ketoacidosis secondary to alcohol withdrawal in the context of fasting has its own complex pathophysiology and can easily mimic the acute insulin deficiency presentation. We present here a rare case of a non-diabetic alcoholic patient who presented in ketoacidosis after a period of reduced intake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087634PMC
http://dx.doi.org/10.14740/jocmr2751wDOI Listing

Publication Analysis

Top Keywords

ketoacidosis non-diabetic
4
non-diabetic adult
4
adult chronic
4
chronic etoh
4
etoh consumption
4
consumption rare
4
rare diabetic
4
diabetic counterpart
4
counterpart ketoacidosis
4
ketoacidosis secondary
4

Similar Publications

Background: Few studies have reported hyperglycemia and diabetic ketoacidosis in patients on dolutegravir (DTG) treatment. This study determined the effect of DTG on fasting blood glucose levels in a cohort of persons living with HIV (PLHIV) in Ghana and initiating DTG regimens.

Methods: A two-year observational longitudinal cohort study conducted from 12th October 2020 to 31st December 2022.

View Article and Find Full Text PDF

Euglycemic ketoacidosis is an acute, life-threatening emergency that is characterized by euglycemia, metabolic acidosis, and ketonemia. It is a well-recognized adverse event in diabetic patients taking sodium-glucose cotransporter-2 inhibitor (SGLT-2 inhibitor). However, there is limited data on SGLT-2 inhibitor-related euglycemic ketoacidosis in non-diabetic patients.

View Article and Find Full Text PDF
Article Synopsis
  • PDC deficiency is a rare mitochondrial disorder that disrupts glucose metabolism, resulting in neurological issues and high lactic acid levels, leading to metabolic acidosis.
  • A 6-year-old patient diagnosed with PDC deficiency experienced severe ketoacidosis when starting the ketogenic diet (KD), but this was managed by adjustments in diet and dextrose supplementation.
  • This case emphasizes the need for careful management of KD, particularly by starting with a lower ketogenic ratio to mitigate the risk of metabolic disturbances in patients with PDC deficiency.
View Article and Find Full Text PDF

Sodium-glucose transporter-2 inhibitors (SGLT2i) are commonly used for the treatment of Type 2 Diabetes Mellitus, offering additional benefits in non-diabetic patients with conditions such as chronic kidney disease and heart failure. However, SGLT2i have been associated with an increased risk of euglycemic diabetic ketoacidosis (DKA). This case series describes three cases of patients who developed euglycemic DKA while taking SGLT2i.

View Article and Find Full Text PDF

A severe pediatric life-threatening metabolic ketoacidosis.

J Diabetes Metab Disord

June 2024

Pediatric Intensive Care Unit, CHU de Caen, F-14000 Caen, France.

This case report presents a 9-year-old child without underlying pathology, with a severe life-threatening non-diabetic metabolic ketoacidosis occurring less than 48 h after the onset of fasting and vomiting. The patient was admitted to the pediatric intensive care unit. He received volume expansion and maintenance fluid therapy which allowed a favorable evolution.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!